Geron (GERN) closed at $1.00 on November 9, 2026, up 0.7% from the previous close, on volume of 5,200,469 shares (30-day average 14,421,394).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 13, 2026 | Calendar Put Spread | 16-Oct : 20-Nov-26 1.5 P | 800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 10:50 AM ET)
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Geron (GERN)
TipRanks (Thu, 5-Nov 8:02 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Wed, 4-Nov 7:03 AM ET)
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Globe Newswire (Wed, 28-Oct 8:00 AM ET)
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 21-Oct 8:00 AM ET)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 19-Oct 4:01 PM ET)
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Tue, 13-Oct 2:52 PM ET)
Business Wire (Mon, 12-Oct 12:14 PM ET)
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron trades on the NASDAQ stock market under the symbol GERN.
As of November 10, 2026, GERN stock price was flat at $1.00 with 3,718,614 million shares trading.
GERN has a beta of 1.38, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.09 to the broad based SPY ETF.
GERN has a market cap of $642.47 million. This is considered a Small Cap stock.
Last quarter Geron reported $60 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-93,120 and exceeded earnings estimates by $.01.
In the last 3 years, GERN traded as high as $5.34 and as low as $.84.
The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
GERN has underperformed the market in the last year with a price return of -6.5% while the SPY ETF gained +12.4%. GERN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.4% and -13.0%, respectively, while the SPY returned -3.2% and -2.4%, respectively.
GERN support price is $.96 and resistance is $1.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.
